Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 30 min ago
Peer-reviewedCC BY 4.0Frontiers in Pharmacology

Model-informed precision dosing of vancomycin and amikacin in critically ill neonates: a pre- and post-intervention study

  • Beyza Kucukyildiz1
  • Merve Kasikci2
  • Irem Iyigun3
  • Hasan Tolga Celik3
  • Karel Allegaert4,5,6,7
  • Nadir Yalcin1
7 affiliations
  1. 1Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University
  2. 2Department of Biostatistics, Faculty of Medicine, Hacettepe University
  3. 3Division of Neonatology, Department of Child Health and Diseases, Faculty of Medicine, Hacettepe University
  4. 4Department of Pharmaceutical and Pharmacological Sciences, KU Leuven
  5. 5Department of Development and Regeneration, KU Leuven
  6. 6Child and Youth Institute, KU Leuven
  7. 7Department of Clinical Pharmacy, Erasmus MC
Read full textPDFDOICite

Abstract

Background: Optimal antimicrobial dosing in neonates is complicated by extreme developmental pharmacokinetic (PK) variability. Traditional therapeutic drug monitoring (TDM) fails to achieve PK/pharmacodynamic (PK/PD) target attainment in this vulnerable population.

Objectives: To evaluate whether implementation of Bayesian model-informed precision dosing (MIPD) improved PK/PD target attainment and exposure dose adjustment compared with conventional TDM in critically ill neonates.

Methods: This pre- and post-intervention design comparing a historical retrospective cohort with a prospective MIPD validation single-center cohort study included 61 neonates receiving vancomycin or amikacin. An initial observational phase with standard dosing (n = 30) was followed by an intervention phase (n = 31) using Bayesian dose adjustment. Secondary outcomes included acute nephrotoxicity, ototoxicity, infection-related inflammatory biomarkers (ΔCRP and ΔProcalcitonin), illness severity (ΔSNAPPE-II), and the treatment-duration-to-hospital-length-of-stay ratio (DOT/LOS) in NICU.

Results: Regarding posterior model concordance, agreement for vancomycin was limited, as evidenced by an overall mean absolute error (MAE) of 5.47 mg/L. For amikacin, concordance was modest (overall MAE: 8.96 mg/L; median absolute error [MdAE]: 1.31 mg/L), reflecting persistent modeling challenges. For vancomycin, therapeutic target attainment was higher with MIPD than with standard dosing (5/30, 16.7% vs. 1/26, 3.8%). Similarly for amikacin, therapeutic target attainment was higher in the MIPD group (10/27, 37.0% vs. 5/26, 19.2%). In an exploratory secondary analysis, ΔSNAPPE-II differed between the standard dosing and MIPD cohorts (−2.5 vs. 0; p = 0.040), favoring standard dosing; as SNAPPE-II is not validated for longitudinal monitoring and the design was non-randomized, this does not constitute evidence of clinical benefit for either strategy. For the overall combined cohort, DOT/LOS was significantly lower in the MIPD group (p = 0.043). No differences in the rates of acute kidney injury (6.9% vs. 10.0%, p = 1.000) or ototoxicity (8.0% vs. 7.1%, p = 1.000) were detected, although the study was underpowered to rule out clinically important differences.

Conclusion: Bayesian MIPD was associated with numerically but not statistically higher pharmacodynamic target attainment (AUC/MIC and Cmax/MIC) for vancomycin and amikacin, and no improvement in clinical outcomes was demonstrated. While amikacin modeling requires further refinement, adequately powered trials are needed to definitively assess the impact of MIPD on safety and clinical outcomes.

Related

  1. A unified population pharmacokinetic model of amikacin in paediatric patients from birth to 18 years for model-informed precision dosing.
    Najla Alabdulkarim, Charlotte Barker, Bairavi Indrakumar +5
    The Journal of antimicrobial chemotherapyPeer-reviewedCC BYFull textObstetrics, gynaecology & paediatricsEurope PMC
  2. Evaluation of Model-Informed Precision Dosing of Cefepime in Critically Ill Patients: A French Before–After Study
    Giuseppe Balice, Soizic Percevault, Sabine Cohen +4
    Therapeutic Drug MonitoringPeer-reviewedLicence not statedFull textGeneral biologyEpidemiology & public healthHAL
  3. Population pharmacokinetics of piperacillin based on multicenter data to support model-informed precision dosing in critically ill women
    Sebastian Greppmair, Sina Pesthy, Michael Zoller +10
    Antimicrobial Agents and ChemotherapyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyPMC
  4. Population Pharmacokinetics and Model-Informed Precision Dosing of Colistin Sulfate in Critically Ill Patients with Carbapenem-Resistant Gram-Negative Infections: A Prospective Pharmacokinetic-Pharmacodynamic Study.
    Tianmin Huang, Lulu Niu, Luyao Qin +9
    Drug design, development and therapyPeer-reviewedCC BY-NCFull textPharmacology & toxicologyEurope PMC
  5. Vancomycin Exposure Dynamics and Clinical Outcomes in Critically Ill Patients: A Retrospective Cohort Study
    Mohamad Amer Nashtar, Jutta Dedy, Stamatina Georgitsi +7
    AntibioticsPeer-reviewedCC BY 4.0Full text1 citedPharmacology & toxicologyHAL

Cite

BibTeXRIS
BibTeX
@article{kucukyildiz2026modelinformed,
  title = {{Model-informed precision dosing of vancomycin and amikacin in critically ill neonates: a pre- and post-intervention study}},
  author = {Beyza Kucukyildiz and Merve Kasikci and Irem Iyigun and Hasan Tolga Celik and Karel Allegaert and Nadir Yalcin},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  month = oct,
  doi = {10.3389/fphar.2026.1985125},
  url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1985125/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Model-informed precision dosing of vancomycin and amikacin in critically ill neonates: a pre- and post-intervention study
AU  - Beyza Kucukyildiz
AU  - Merve Kasikci
AU  - Irem Iyigun
AU  - Hasan Tolga Celik
AU  - Karel Allegaert
AU  - Nadir Yalcin
PY  - 2026
DA  - 2026/10/16
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1985125
UR  - https://www.frontiersin.org/articles/10.3389/fphar.2026.1985125/full
AB  - Background: Optimal antimicrobial dosing in neonates is complicated by extreme developmental pharmacokinetic (PK) variability. Traditional therapeutic drug monitoring (TDM) fails to achieve PK/pharmacodynamic (PK/PD) target attainment in this vulnerable population.  Objectives: To evaluate whether implementation of Bayesian model-informed precision dosing (MIPD) improved PK/PD target attainment and exposure dose adjustment compared with conventional TDM in critically ill neonates.  Methods: This pre- and post-intervention design comparing a historical retrospective cohort with a prospective MIPD validation single-center cohort study included 61 neonates receiving vancomycin or amikacin. An initial observational phase with standard dosing (n = 30) was followed by an intervention phase (n = 31) using Bayesian dose adjustment. Secondary outcomes included acute nephrotoxicity, ototoxicity, infection-related inflammatory biomarkers (ΔCRP and ΔProcalcitonin), illness severity (ΔSNAPPE-II), and the treatment-duration-to-hospital-length-of-stay ratio (DOT/LOS) in NICU.  Results: Regarding posterior model concordance, agreement for vancomycin was limited, as evidenced by an overall mean absolute error (MAE) of 5.47 mg/L. For amikacin, concordance was modest (overall MAE: 8.96 mg/L; median absolute error [MdAE]: 1.31 mg/L), reflecting persistent modeling challenges. For vancomycin, therapeutic target attainment was higher with MIPD than with standard dosing (5/30, 16.7% vs. 1/26, 3.8%). Similarly for amikacin, therapeutic target attainment was higher in the MIPD group (10/27, 37.0% vs. 5/26, 19.2%). In an exploratory secondary analysis, ΔSNAPPE-II differed between the standard dosing and MIPD cohorts (−2.5 vs. 0; p = 0.040), favoring standard dosing; as SNAPPE-II is not validated for longitudinal monitoring and the design was non-randomized, this does not constitute evidence of clinical benefit for either strategy. For the overall combined cohort, DOT/LOS was significantly lower in the MIPD group (p = 0.043). No differences in the rates of acute kidney injury (6.9% vs. 10.0%, p = 1.000) or ototoxicity (8.0% vs. 7.1%, p = 1.000) were detected, although the study was underpowered to rule out clinically important differences.  Conclusion: Bayesian MIPD was associated with numerically but not statistically higher pharmacodynamic target attainment (AUC/MIC and Cmax/MIC) for vancomycin and amikacin, and no improvement in clinical outcomes was demonstrated. While amikacin modeling requires further refinement, adequately powered trials are needed to definitively assess the impact of MIPD on safety and clinical outcomes.
SN  - 1663-9812
ER  -